Institute for Myeloma & Bone Cancer Research-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2020

  1. Once-weekly (70 mg/m2) vs twice-weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials

    Cancer Medicine, Vol. 9, Núm. 9, pp. 2989-2996